Free Trial

Adaptimmune Therapeutics (ADAP) SEC Filings & 10K Form

Adaptimmune Therapeutics logo
$0.29 0.00 (-1.37%)
As of 05/20/2025 04:00 PM Eastern

Recent Adaptimmune Therapeutics SEC Filings

DateFilerForm TypeView
05/13/2025
6:35 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/01/2025
3:15 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/25/2025
7:02 AM
Adaptimmune Therapeutics (Filer)
Form DEF 14A
04/15/2025
7:00 AM
Adaptimmune Therapeutics (Filer)
Form PRE 14A
04/14/2025
3:10 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/24/2025
3:40 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/24/2025
3:44 PM
Adaptimmune Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/20/2025
6:09 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/20/2025
4:34 PM
Adaptimmune Therapeutics (Issuer)
Brewer Joanna Elizabeth (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2025
4:35 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2025
4:30 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2025
4:31 PM
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2025
4:32 PM
Adaptimmune Therapeutics (Issuer)
Piccina Cintia (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2025
4:33 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2025
8:31 AM
Adaptimmune Therapeutics (Subject)
Two Seas Capital LP (Filed by)
Form SCHEDULE 13G
02/12/2025
9:25 AM
Adaptimmune Therapeutics (Subject)
BAILLIE GIFFORD & CO (Filed by)
Form SCHEDULE 13G/A
01/17/2025
8:15 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2025
8:16 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2025
8:17 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2025
8:17 PM
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/17/2025
2:07 PM
Adaptimmune Therapeutics (Subject)
Norry Elliot (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/17/2025
1:42 PM
Adaptimmune Therapeutics (Subject)
Rawcliffe Adrian (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/17/2025
1:50 PM
Adaptimmune Therapeutics (Subject)
Bertrand William C JR (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/17/2025
1:59 PM
Adaptimmune Therapeutics (Subject)
Lunger John (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/15/2025
3:15 PM
Adaptimmune Therapeutics (Issuer)
Bertrand William C JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2025
3:16 PM
Adaptimmune Therapeutics (Issuer)
Lunger John (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2025
3:17 PM
Adaptimmune Therapeutics (Issuer)
Norry Elliot (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2025
3:18 PM
Adaptimmune Therapeutics (Issuer)
Piccina Cintia (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2025
3:19 PM
Adaptimmune Therapeutics (Issuer)
Rawcliffe Adrian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2025
2:43 PM
Adaptimmune Therapeutics (Subject)
Lunger John (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/15/2025
2:50 PM
Adaptimmune Therapeutics (Subject)
Norry Elliot (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/15/2025
2:34 PM
Adaptimmune Therapeutics (Subject)
Rawcliffe Adrian (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2025
9:30 AM
Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
Form SCHEDULE 13G/A
12/19/2024
6:40 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/05/2024
4:17 PM
Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
Form SCHEDULE 13G/A
11/13/2024
8:04 AM
Adaptimmune Therapeutics (Subject)
Matrix Capital Management Company, LP (Filed by)
Form SC 13G/A
11/13/2024
8:10 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/01/2024
4:00 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/23/2024
3:15 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/12/2024
6:23 AM
Adaptimmune Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/12/2024
6:05 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
Elon just did WHAT!? (Ad)

As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.

Click here to see how to claim your stake before they launch to avoid missing out.
08/02/2024
6:00 AM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/16/2024
3:30 PM
Adaptimmune Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ADAP) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners